Kalydeco expansion confirmed in Wales
The All Wales Medicine Strategy Group (AWMSG) has approved the use of the transformational precision medicine Kalydeco in Wales for three people with one of eight rare gating mutations.
People with the G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D mutations will now be granted access to Kalydeco, which evidence suggests significantly increases life expectancy and drastically reduces the amount of time people with cystic fibrosis spent in hospital.
The Cystic Fibrosis Trust made the case for this extension of use alongside clinicians involved in the care of the three people, to bring Wales in line with the rest of the UK, where the treatment is already available for these mutations.
Nick Medhurst, Policy Manager at the Trust, said: ‘We warmly welcome this decision by the AWMSG, and hope this will greatly benefit the people in Wales with these mutations.
“We are glad to have played a part in providing evidence to support this decision and look forward to Kalydeco being made available to other people, so that those who could benefit will have access to the medicine as quickly as possible.”
The Trust's Stopping the Clock campaign calls for fairer access to precision medicines for people with cystic fibrosis.
This news item was originally featured on our old website, dated 10/12/2015, and may have been edited since.